Scholar Rock Reports $110M Net Loss in Q2 2025, Advances Product Pipeline

Scholar Rock Holding Corporation reported significant financial results for the second quarter of 2025, revealing a net loss of $110.0 million, or $0.98 per share, compared to a net loss of $58.5 million, or $0.60 per share, in the same period of the previous year. For the first half of 2025, the company recorded a net loss of $184.8 million, up from $115.4 million in the first half of 2024. Total operating expenses for the second quarter reached $112.1 million, an increase of 88.4% from $59.5 million year-over-year, driven primarily by a 47.3% rise in research and development expenses, which totaled $62.4 million.

The company’s financial position showed a decrease in total assets, which fell to $340.0 million as of June 30, 2025, down from $474.9 million at the end of 2024. This decline was largely attributed to a reduction in cash and cash equivalents, which decreased to $152.9 million from $177.9 million, and a significant drop in marketable securities, which fell from $259.4 million to $142.1 million. The accumulated deficit also widened to $1.1 billion, reflecting ongoing investments in research and development and operational costs.

Strategically, Scholar Rock has made notable advancements in its product pipeline, particularly with its lead candidate, apitegromab, which is under priority review by the FDA with a target action date of September 22, 2025. The company has also expanded its anti-myostatin program with the introduction of SRK-439, a novel monoclonal antibody, and plans to submit an investigational new drug application for this candidate in the second half of 2025. Additionally, the company completed the Phase 1 DRAGON trial for SRK-181, which targets cancers resistant to checkpoint inhibitors, in June 2025.

Operationally, Scholar Rock has seen a substantial increase in its workforce, contributing to higher general and administrative expenses, which rose to $49.7 million in the second quarter, a 190.3% increase from the previous year. The company is also preparing for the commercial launch of apitegromab in the U.S. and Europe, anticipated in late 2025 and 2026, respectively. The company’s management has indicated that it expects to continue incurring significant operating losses as it advances its clinical programs and builds its commercialization capabilities.

Looking ahead, Scholar Rock anticipates that its existing cash and marketable securities will be sufficient to fund operations into 2027. However, the company acknowledges the need for additional capital to support ongoing clinical development and commercialization efforts. The management remains focused on executing its strategic initiatives while navigating the challenges inherent in the biopharmaceutical industry.